Kilickap, S. Et Al. 2021. Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3 .

Kilickap, S., Sezer, A., Gumus, M., Bondarenko, I., Ozguroglu, M., Gogishvili, M., ... Turk, H. M.(2021). Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3.

Kilickap, S. Et Al. "Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC," JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021

Kilickap, S. Et Al. "Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021

Kilickap, S. Et Al. (2021) . "Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3.

@article{article, author={S. Kilickap Et Al. }, title={Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2021}